Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14

Benzinga · 2d ago
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.